Prasad S. Adusumilli, MD, on Solid Tumors: CAR T Cells and Immune Checkpoint Blockade
2017 ASCO-SITC Clinical Immuno-Oncology SymposiumPrasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherapy.
Related Videos
Holger N. Lode, MD: Neuroblastoma Survival Update
Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-c...
Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy
Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
Stephen Gottschalk, MD, on CAR T Cells for Solid Tumors: What Are the Challenges?
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their a...
Holger N. Lode, MD: Neuroblastoma Survival Update (German Language Version)
Holger N. Lode, MD, of the University of Greifswald, discusses in German the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO an...
Howard Kaufman, MD, on Merkel Cell Carcinoma: Treatment Update
Howard Kaufman, MD, of Rutgers Cancer Institute of New Jersey, discusses a subgroup analysis of efficacy results on avelumab in chemotherapy-refractory metastatic Merkel cell carcinom...
